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Abstract
Background: Dry powder inhalers (DPIs) are the most commonly used devices in asthma treatment in the Nordic
countries. As new DPIs become available, patients are likely to be exposed to more than one type of device, with
variable optimal handling. The aim was to examine real life storage and retention of multidose DPIs in patients with
asthma.
Methods: This patient-reported survey on real life storage and retention of DPIs included asthma patients using
multidose DPIs. Basic patient characteristics, information on inhaler use and storage, check of expiry date, and
concurrent inhaler use was examined using an on line questionnaire.
Results: A total of 738 patients were included with a median age of 41 years, out of which 83 % were women.
Sixty-three per cent reported storage conditions pre-defined as risk locations for their maintenance inhaler and
38 % of the responding patients had more than one maintenance inhaler in use at the same time. Two thirds
of the study population checked inhaler expiry date less than monthly or not at all. Use after expiry date was
frequently reported. Two thirds of the patients had not received information on DPI storage, either from their
doctor and/or nurse or at the pharmacy.
Conclusions: This patient reported survey indicates that two thirds of the patients store their inhaler devices in
suboptimal conditions, and only a minority had received instruction regarding inhaler handling. Non awareness
of inhalers’ expiry dates and use of more than one maintenance inhaler simultaneously was common. As inhaler
mishandling may impact device functionality, improved communication and patient education is needed.
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Background
A number of different devices are used for drug delivery
to the lungs in the treatment of asthma, e.g. dry powder
inhalers (DPIs), pressurized metered dose inhalers
(pMDIs) and soft mist inhalers (SMIs). Of these, DPIs are
the most commonly used inhalers in the Nordic countries.
In Norway, the past years have witnessed an increase in
available DPI devices to currently 12 different device pro-
viders. Combinations of inhaled corticosteroids (ICS) and
long-acting beta2 agonists (LABA) were the top two reim-
bursed prescribed drugs in 2012 [1]. Hence, treatment of
asthma have a substantial impact on health care costs.
The asthma prevalence has increased in Norway over
the last four decades, and is reported to be between 8
and 12 % [2, 3]. GINA guidelines recommend a stepwise
approach to reach optimal asthma control [4]. This
should include not only receiving a correct diagnosis,
but also a choice of inhaled therapy made in agreement
between the physician and the patient, training on
correct device use [5], and information on inhaler hand-
ling, storage, and retention. On the other hand, lack of
treatment adherence and incorrect daily use may occur
in up to 94 % of asthma patients [6, 7]. Hence, each of
these steps are important to achieve asthma control.
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Due to effective modern inhalation treatment, patients
can today live a normal active life, and may have mul-
tiple inhalers available for use in different locations ac-
cording to their lifestyle. Asthma patients are likely to be
exposed to more than one type of inhaler concurrently
during their treatment journey. Suboptimal inhaler tech-
nique [8] and inhaler mishandling [9] are still common
in real life use. Lack of device continuity may increase
these problems [10, 11]. To ensure optimal inhaler use,
patient's preference [12] and education [13] and training
of health care professionals in device handling [5] need
to be in focus. The fact that inhalers differ in inhalation
techniques, time in-use, and storage conditions needs
increased awareness.
DPIs are breath actuated and more easy to use as there
is no need to coordinate the inhalation, in contrast to
most pMDIs. A potential drawback, however, is that
DPIs can be sensitive to humidity, and in vitro studies
have shown that the fine particle dose and the actual
delivered dose may be negatively affected by storage
in humid conditions [14, 15]. Differences in the re-
sistance to humidity between different inhalers have
been reported, likely due to the different technical ap-
proaches developed to protect the respective dry pow-
der from humidity [15]. A potential decrease of the
dose reaching the lungs may eventually impact the
clinical outcomes and infer decreased drug efficacy
and safety. Still, the full clinical impact has not been
indisputably established.
The DPIs available today have differences in shelf-life,
time in-use and storage conditions such as protection
against humidity (Table 1). In Norway, the drug reim-
bursement for chronic diseases allows prescription cov-
ering a 3 months period, during which patients may
store drugs outside the controlled conditions in a phar-
macy. However, the actual knowledge of asthma patients’
awareness of and compliance to correct handling of
DPIs in daily life is scarce. In the complex approach of
achieving full asthma control, this is an important area
in need of further investigation. The present patient-
reported survey aimed at investigating asthma patients’
storage and retention of dry powder inhalers in everyday
use.
Methods
Study design and patient population
A patient reported survey was conducted in collabor-
ation with a pharmacy chain (Boots A/S, Norway). No
formal sample size calculation was performed. The
pharmacy administered the survey via e-mail to all indi-
viduals who had indicated an interest in receiving infor-
mation from the pharmacy on asthma and/or allergy.
Based on the assumption that 50 % of the approximately
20,000 patients included in the pharmacy’s asthma and
allergy customer register were asthmatics using DPIs,
and with an expected response rate of 10 %, the sample
size was estimated to 1,000 patients. Patients had to
1) confirm their diagnosis of asthma; and 2) accept
Table 1 Number of doses, shelf life and storage of the most commonly used multidose dry powder inhalersa
Inhaler Doses Shelf life (unopened) Time in-use (opened) Recommended storage conditions
Diskus/Accuhaler 60 1.5–3 years (depending on
drug strength)
1.5–3 years Do not store above 30 °C. Store in a dry place.
Inhaler is sealed in a foil overwrap, which should only be opened
when it is to be used for the first time.
Easyhaler 200 3 years 6 months Store in the original package.
When in use, do not store above 30 °C and store protected
from moisture.
Ellipta 30 2 years 6 weeks Do not store above 25 °C
Store in the original package in order to protect from moisture.
Genuair 60 3 years 90 days Keep the inhaler protected inside the sealed pouch until the
administration period starts.
Nexthaler 120 3 years 6 months Do not store above 25 °C.
Store in the original package in order to protect from moisture.
Novolizer 200 3 years 6 months Store in the original package.
When in use, keep the device tightly closed in order to protect
from moisture.
Spiromax 120 3 years 6 months Do not store above 25 °C.
Keep the mouthpiece cover closed after removal of the
foil wrapping.
Turbuhaler 200 2 years 2 years Do not store above 30 °C.
a For further details reference to respective inhaler’s Summaries of Product Characteristics (SPCs)
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participation in the study to have on line access to
the self reported questionnaire. In addition, a patient-
confirmed prescription of inhaled treatment by a
multi dose DPI during at least 3 months prior to in-
clusion was required. The survey included questions
on basic patient characteristics (such as age, gender,
and number of concomitant inhalers for maintenance
and as-needed use), and covered also different aspects
of inhaler storage (e.g. actual storage conditions and
instructions provided prior use) and retention (e.g.
usage pattern and expiry date awareness). Primary main-
tenance defined as the most commonly used inhaler.
Study objectives
This patient-reported survey aimed at investigating the
real life handling of multi dose dry powder inhalers for
the treatment of asthma, including storage under non-
optimal conditions, use after expiry date, use of con-
comitant inhalers, and how instructions regarding device
handling were given.
Study variables
The study variables included information such as time
on DPI treatment, number of concurrent multi-dose
DPI inhalers, frequency of inhaler expiry date checks, use
of inhaler after expiry date, storage of inhaler in warm or
humid conditions, and information on how patients were
instructed in how to store and retain their inhaler devices.
Data are presented using descriptive statistics.
Definition of storage conditions
The following storage conditions, predefined according
to study protocol, were considered as risk locations for
DPI storage: warm and humid conditions (summer
outdoors, bathroom, gym, or indoor swimming pool),
humid conditions (winter outdoors), and warm condi-
tions (car, bag).
Results
A total of 738 patients (median age 41 years; 83 %
women) fulfilled the criteria and completed the self-
reported questionnaire. Twenty-five percent (25 %) of
the patients were between 36–45 years, 30 % were youn-
ger and 45 % of the respondents were older than
45 years. A total of 10 % were >65 years. The majority of
patients (71 %) had used a DPI for more than 5 years,
whereas only 4 % had used their DPI for between
3 months and 1 year. Overall, 81 % reported on having an
inhaler for maintenance use. No patient characteristics or
other information was available for the non-responders.
The primary maintenance inhaler was stored in the
bathroom by 42 % of the patients and either in handbag
or pocket by an additional 21 %. For the secondary
maintenance inhaler the figures were almost the opposite,
with 43 % storage in handbag or pocket, and 18 % in the
bathroom. Overall, storage according to the predefined
risk locations was reported by 63 % of the patients for the
primary, 61 % for the second and 41 % for the third main-
tenance inhaler, respectively.
More than half of the patients (63 %) either did not
check the inhaler’s expiry date at all or checked it less
frequently than once a month (Fig. 1a). Occasional or
frequent use after expiry date was reported by 30 % of
the patients, while an additional 18 % were unaware of
the expiry date (Fig. 1b). Seventy-nine percent (79 %) of
the patients indicated that they used their inhaler until it
was empty. There was a trend (non-significant) towards
a less thorough check of expiry dates with increased
number of inhalers. Age did not impact the level of
expiry date checks.
Instructions on how to store and retain their DPI had
only been received by 31 % of the patients. Out of these,
45 % had received the information from the package in-
sert, 29 % was informed at the pharmacy, and another
24 % of the patients stated that they had received the
information from their doctor and/or nurse. Males
and patients younger than 45 years were more likely
to have received instructions on DPI storage by the
doctor and/or nurse (28 and 26 %, respectively), than
females and patients >45 years (23 and 22 %, respectively)
(Table 2).
Thirty-eight per cent (38 %) of the responding patients
stated that they had more than one maintenance inhaler
in use at the same time. The majority of these (30 % of
the study population) had 2 simultaneous maintenance
inhalers, very few (2 %) used four or more inhalers con-
currently. The majority of the patients (83 %) reported
having a separate reliever medication for symptom con-
trol (as needed use), and one third of the patients (29 %)
had more than one as needed inhaler in use at the same
time. Most common storage place was in a bag, 42 %.
Only 4 % of the patients reported storage of their as
needed inhaler according to the instructions.
Discussion
Available DPIs have differences in shelf life, time in-use
and storage conditions. Failure to comply with the re-
quirements may impact the functionality of the device.
In this patient reported survey on asthma patients
treated with multi dose dry powder inhalers, a substan-
tial proportion of asthma patients have their DPIs stored
in conditions with risk of exposure to humidity. The
patients commonly use their DPIs after expiry date. Fur-
ther, very few patients had received any information
regarding inhaler storage and retention, and for the
ones who had, the main source of information was
the package insert, not their health care contact or
pharmacist. Males were more likely to receive information
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at their health care center compared to females, which
may reflect a gender-linked behavior in health care.
The present study comes with a number of limitations.
The design is based on patient reported data only, hence
asthma diagnosis and actual treatment with DPI could
not be verified, and it is well known that self-reported
medication use may be different than actual use. In
internet-based research surveys, response representative-
ness is more important than response rate [16]. In our
study, the included population consists of individuals
who had actively indicated interest in asthma and/or
allergy and may represent an asthma population with
more than average knowledge and motivation for asthma
treatment. Hence, one could speculate that the know-
ledge of correct use and storage of inhalers in the gen-
eral asthma population might be even lower than what
is seen in our study. The questionnaire and the storage
conditions were defined for the present study only, and
were thus not validated or standardized. The gender dis-
tribution among the responders can be considered
skewed. Although, the study has a low response rate, the
results are well in accordance with other studies on real
life challenges in asthma care.
Most inhalers have recommendations on storage tem-
peratures and humidity, and some inhalers even need
humidity protection storage until start of use (Table 1).
Of the currently available DPIs, Diskus and Turbuhaler
have the by far longest time in-use, but they may differ
in tolerability to humidity. However, this study was not
designed to evaluate quality differences between in-
halers, but to investigate which conditions an inhaler is
exposed to in real life and thus should be able to tolerate.
The present study shows that 63 % of the responders store
their maintenance inhaler(s) in sub-optimal storage condi-
tions. This is well in keeping with a previous study, where
required storage instructions for inhalation capsules was
lacking by 84 % of the patients [17].
Concurrent use of multiple inhalers could potentially
lead to prolonged use of the inhalers. Fewer inhalations
from each inhaler results in a high number of doses left
in the inhaler at the expiry date, encouraging continued
use. In the present asthma study, a clear majority of the
patients reported being more or less unaware of the
expiry date of their DPI. This may be further compli-
cated if the patient has more than one type of inhaler
with different time in-use.
Conclusions
The present patient reported survey indicates that
two third of the patients store their inhaler devices in
suboptimal conditions, and only a minority had re-
ceived instruction regarding inhaler handling. Two
thirds of the study population checked inhaler expiry
date less than monthly or not at all. Use of more
than one maintenance inhaler simultaneously was
common. Overall, this may impact the functionality
of the device and result in sub-optimal treatment. Im-
proved communication and patient education to en-
sure adherence to the different requirements of each
inhaler device is needed.
a b
Fig. 1 Patient-reported (a) frequency of control of DPI expiry date; and (b) use after DPI expiry date (per cent of patients)
Table 2 Patient-reported source of information on dry powder
inhaler storage and retention, divided by gender and age below
or equal to, or above 45 years
Male Female ≤45 years >45 years
Doctor/nurse, % 28 23 26 22
Pharmacy, % 26 30 29 29
Leaflet, % 43 45 44 46
Other, % 3 2 1 3
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